This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

LIPID study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study was a double-blind randomised placebo controlled study of the effect of pravastatin in patients with a history of myocardial infarction or unstable angina who had a broad range of cholesterol levels.

Patients randomised to pravastatin showed a 20-30% relative risk reduction for a range of cardiovascular including:

  • overall mortality
  • myocardial infarction
  • stroke

This study suggests that any patient with a previous diagnosis of unstable angina or myocardial infarction should receive a statin.

For every 1000 patients treated for 6.1 years the following end-points were avoided:

  • 30 deaths
  • 28 non-fatal myocardial infarctions
  • 9 non-fatal strokes
  • 23 coronary bypass operations
  • 20 coronary angioplasties
  • 82 hospital admissions for unstable angina

Reference:

  • (1) LIPID study group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl. J. Med. 339, 1349-57

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.